ClinicalTrials.gg
CompletedNCT02614872Updated Sep 1, 2021

Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation

A Phase 2 interventional study of GLASSIA® and Institution standard of care (SOC) in Transplantation, Lung Rejection, sponsored by Kamada, Ltd.. Completed at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-01.

Sponsored by Kamada, Ltd. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study evaluates the safety and efficacy of intravenous GLASSIA® treatment in lung transplantation.

Read the detailed description

There is clinical rationale to advocate the use of AAT(GLASSIA) therapy during episodes of lung inflammation, including acute and chronic rejection. AAT may provide more specifically targeted prevention of pathogenic inflammation, superior to that of general immunosuppressants, with little risk. AAT is the main inhibitor of Neutrophil elastase(NE) in the lower airways and patients with AAT deficiency have low concentrations of the protein in this region of the lung. This explains the proteinase/antiproteinase theory of the development of emphysema in deficient patients in which the amount of elastase released in the lung exceeds the amount of AAT. The net result is persistence of elastase activity leading to lung destruction and the pathological changes of emphysema. Administration of AAT will help to prevent further destruction of the lung architecture and reduce the inflammatory dysregulation that causes pulmonary dysfunction. It is expected that by attacking a specific and previously untreated key component of the pathophysiological cycle of BOS, AAT therapy would decrease the prevalence of BOS in lung transplant recipients and prolong life expectancy of these patients. This will be an open label study in order to ensure safety, in the frame of POC study.

02

Conditions studied

  • Transplantation, Lung Rejection
03

In context

Lead sponsor

Kamada, Ltd. is the lead sponsor of 11 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and dated .
  2. Age ≥18 years.
  3. Subject is planned to undergo first single or double lung transplant (including heart-lung transplant) as per standard implantation procedure.

Exclusion criteria

Exclusion Criteria:

  1. Subject has immunoglobulin A (IgA) deficiency and known anti IgA antibodies.
  2. Known history of OR positive serological evidence at the time of screening for hepatitis A virus (HAV), virus (HBV), virus (HCV), Parvovirus B19 (PVB19) or (HIV) Type 1/2 infection
  3. Subjects with a history of severe immediate reactions, including allergies, anaphylaxis to plasma products or any human proteins of different source.
  4. Pregnant or lactating women at entry to study and women of child bearing potential, who are unwilling to agree to continue to use acceptable methods of throughout the study.
  5. Presence of psychiatric/ mental disorder or any other medical disorder which might impair the subject's ability to give or to comply with the requirements of the study protocol.
  6. Alcohol abuse or history of alcohol abuse.
  7. Illegal drugs.
  8. Candidate for organ transplantation other than first lung or heart-lung transplantation
  9. bronchial stenosis unresponsive to dilation and/or stenting
  10. Participation in another interventional clinical trial within 30 days prior to baseline visit.
  11. Inability to attend scheduled clinic visits and/or comply with the study protocol.
  12. Any other factor that, in the opinion of the investigator, would prevent the subject from complying with the requirements of the protocol.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    GLASSIA®

    Glassia® IV treatment additional to Institution standard of care (SOC) for first lung transplant subjects according to Investigator discretion.

    Drug: GLASSIA® and Institution standard of care (SOC)

  • No intervention
    Institution standard of care (SOC)

    Institution standard of care (SOC) for first lung transplant subjects according to Investigator discretion.

Interventions

  • DrugGLASSIA® and Institution standard of care (SOC)

    Alpha-1 Antitrypsin (AAT) \[GLASSIA®\] add-on pharmacotherapy and Institution standard of care (SOC)

    Also known as: GLASSIA and Institution standard of care (SOC)

06

What researchers measure

Primary outcomes

  1. Incidence of subjects experiencing AEs and/or SAEs

    Incidence of subjects experiencing causally related AEs and/or SAEs

    Time frame: during the study

  2. Incidence and rate of Acute Rejection

    Incidence and rate of Acute Rejection

    Time frame: per year

Secondary outcomes

  1. Annual rate (per subject) of pulmonary infections

    Annual rate (per subject) of pulmonary infections

    Time frame: per year

  2. Incidence of subjects who develop Bronchiolitis Obliterans

    Incidence of subjects who develop Bronchiolitis Obliterans

    Time frame: during the study

  3. Changes in Pulmonary Function Test

    Changes in Pulmonary Function Test

    Time frame: Change from baseline and overall effect

07

Study locations

1 site
  • Pulmonary Institute - Rabin Medical Center
    Petach Tikva, Israel
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2016 to primary completion in Apr 2019, 32 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2015
First posted
Nov 25, 2015
StartActual
Jul 26, 2016
Primary completionActual
Apr 11, 2019
CompletionActual
May 7, 2019
Last update
Sep 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02614872
Lead sponsor
Kamada, Ltd.
Responsible party
Sponsor
First posted
Nov 25, 2015
Start date
Jul 26, 2016
Primary completion
Apr 11, 2019
Completion
May 7, 2019
Last update
Sep 1, 2021

Study contacts

Mordechai Kramer, MD
principal investigator · Pulmonary institute, Rabin Medical Center, Israel.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion